Abstracts tier drug benefit plan at a managed care plan in Toledo-Ohio, were reviewed retrospectively. The top ten therapy classes based on net costs to the health plan were selected for analysis. The records for these classes were extracted using the Rx Clients Report v 5.0 software at the health plan. Data were analyzed using Microsoft Excel 2000. RESULTS: On average 1) PMPM ingredient costs increased 16.5% for the preferred drugs and decreased 7.4% for the non-preferred drugs; 2) PMPM utilization increased 19.3% for the preferred drugs and decreased 12.7% for the non-preferred drugs and; 3) Ingredient cost per prescription increased 2.8% for the preferred drugs and also increased 4.7% for the non-preferred drugs. The increase in the PMPM ingredient costs and PMPM utilization maybe due to the utilization of the most expensive preferred drugs on the formulary. The ingredient costs per prescription were not skewed either towards the preferred or the non-preferred drugs. CONCLUSION: The implementation of a three-tier drug co-payment caused a decrease in the PMPM ingredient costs and PMPM utilization of the non-preferred drugs. It generated cost-savings to the managed care plan over a period of two years by shifting the members from high cost non-preferred drugs to the lower cost preferred drugs.
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PRACTICAL ASPECTS OF DESIGNING AND CONDUCTING PHARMACOECONOMIC STUDIES IN JAPAN Doherty J, Sato K Pharmacia Inc, Tokyo, Japan
Economic evaluation of medical technologies in Japan is challenging because of a lack of data sources. OBJECTIVE: This paper reviews the data sources available for conducting pharmacoeconomics research in Japan, and discusses health policy reforms that may increase the demand for pharmacoeconomics studies in the future. METHODS: A literature review of pharmacoeconomic studies was conducted in both English (MEDLINE OHE-HEED) and Japanese publications (JAPICDOC) to identify the typical data sources used in these studies. Reflecting on first hand experience conducting outcomes research in Japan, we summarized (percent of studies utilizing the different data source types) and commented on the data sources. RESULTS: A total of 42 published studies were found in the Japanese and English literature from 1980-2001. Typical sources identified for resource utilization data included: clinical trials (62%), epidemiology/case studies (43%), patient chart reviews (52%), expert panels (12%). Sources for clinical efficacy or disease state transition probabilities included: clinical trials (60%), epidemiology/case studies (36%), patient chart reviews (29%), expert panels (12%). The cost data sources identified were: 1) national uniform reimbursement fees (98%)-Japanese Ministry of Health, Labor and Welfare (MHLW), 2) micro-cost studies (2%). The MHLW uniform fees represent costs from the health insurance plan viewpoint, and therefore are relevant in drug price negotiations with the MHLW. Demand for pharmacoeconomic data may increase because of: 1) upcoming MHLW pharmaceutical pricing and/or health insurance system reforms; 2) new regulatory committees e.g. NICE. CONCLUSION: Access to data sources for pharmacoeconomic research is generally known to be limited in Japan, however several published studies effectively overcame such limitations. Compared to other countries, however, detailed population-based data are still relatively unavailable. Upcoming health care reforms may increase the demand for pharmacoeconomic data in Japan, thus, increasing the demand for better sources of data typically needed for these studies. 
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OUTCOMES AND COSTS OF ACUTE TREATMENT OF TRAUMATIC BRAIN INJURY
OBJECTIVE:
Although there are nearly a quarter of a million hospitalizations for traumatic brain injury (TBI) in the U.S. each year, economic data on TBI treatment are limited. The purpose of this study was to estimate the outcomes and costs of acute inpatient treatment of TBI. METHODS: Using a large, geographically-diverse, multihospital database, we examined inpatient records for persons aged 16 years or older who were hospitalized for TBI between January 1, 1997 and June 30, 1999. Patients were stratified by TBI severity using an adaptation of the Abbreviated Injury Scale for administrative data (ICD/AIS), as follows: 2, "moderate"; 3, "serious"; 4, "severe"; and 5, "critical". Patient characteristics, patterns of treatment, and outcomes and costs were examined by injury severity and mechanism of injury. Costs of treatment were estimated from billed charges using costto-charge ratios from the Medicare Prospective Payment System. RESULTS: Of 8,717 study subjects identified, 12.5% had moderate, 44.8% serious, 29.6% severe, and 13.2% critical TBI. Falls were the most common reported cause of injury (40.8%), followed by motor-vehicle accidents (39.3%), blows to the head (11.3%), and gunshot wounds (2.4%). Average length of stay in hospital ranged from 6.7 days for moderate TBI to 17.5 days for critical TBI. The overall rate of death in hospital was relatively low among patients with moderate (1.3%), serious (5.7%), and severe (8.7%) TBIs, but much higher among the most critically injured patients (52.0%). Costs of hos-pitalization averaged $8,189 for moderate, $14,603 for serious, $16,788 for severe, and $33,537 for critical TBI. Costs also varied by injury type, averaging $20,084 for gunshot wounds, $20,522 for motor-vehicle accidents, $15,860 for falls, and $19,949 for blows to the head. CONCLUSIONS: The economic burden of TBI in the acute-care setting is substantial; treatment outcomes and costs vary considerably by TBI severity and mechanism of injury.
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PATIENT WILLINGNESS TO PAY FOR COGNITIVE PHARMACY SERVICES IN AMBULATORY CARE SETTINGS
Olagundoye A, Daftary MN, Dutta A, Wakijra C Howard University, Washington, DC, USA Pharmaceutical care is known to help improve patient quality of life, reduce adverse events and help reduce healthcare costs. OBJECTIVES: This paper aims to identify the current level of cognitive pharmacy services that patients receive in ambulatory pharmacy settings and the amount patients are willing-to-pay for these services. METHODS: A self-administered questionnaire was constructed and tested for validity. The questionnaire was distributed at two randomly selected ambulatory care pharmacies in Maryland. The instrument asked questions regarding demographics, current level of cognitive pharmacy services the patient was receiving and the dollar amount the patient was willing-to-pay for the service. RESULTS: 91 people responded. Thirty-one percent of the respondents were between the ages of 45 and 65 and approximately 13% of the respondents were Hispanic. The majority of the respondents were female (60%) and about 33% had completed trade school or college. The major insurance type was HMO/Medicare (41.8%) and about 31.2% of respondents reported an annual income between $20-30K. Sixty-three percent of respondents reported a household size of two to four persons. Almost 80% of respondents reported their perceived health status to be good/very good. Almost one-half (48.4%) of respondents reported never receiving any detailed counseling about their medications, and 60% of respondents reported never receiving any monitoring services. The respondents were willing-to-pay $0-10 (58.2%) and $11-20 (29.7%) for a single pharmaceutical care evaluation. The respondents were willing-to-pay $41-50 (16.5%) for a pharmaceutical care evaluation with a year of monitoring by the pharmacist. Although, 36.3% of the respondents were only willing-to-pay between $0-10. The majority of respondents reported that insurance companies should cover cognitive pharmacy services. CONCLUSIONS: The results suggest that the majority of the respondents are not receiving cognitive pharmacy services; although, many of them would be willing-to-pay for this type of service.
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POLISH GUIDELINES FOR CONDUCTING BUDGET IMPACT ANALYSIS IN THEIR COMPARISON TO EXISTING GUIDANCE ON BUDGET IMPACT ANALYSIS IN OTHER COUNTRIES
Orlewska E 1 , Mierzejewski P 2 , Kanavos P 3 1 Medical University of Warsaw, Warsaw, Poland; 2 Ministry of Health, Warsaw, Poland; 3 Harvard University Medical School, Boston, MA, USA OBJECTIVES: While pharmacoeconomic research is often used as a tool to assist decision on product reimbursement, Budget Impact Analysis (BIA) is increasingly required by decision-makers to ascertain the macroeconomic consequences of new product reimbursement in addition to proof of cost-effectiveness. BIA provides insight into financial consequences of reimbursing a new technology. Poland is in the process of drafting countryspecific guidelines for BIA, positioned as complementary to economic evaluation in decision making. The aim of this study is to compare project of Polish BIA guidelines with existing international guidance, highlighting areas of agreement and dissent. METHODS: Guidelines from five countries (Australia, Canada, Netherlands, England & Wales, France, USA) were reviewed, analyzed and comparison was undertaken. The following areas were analysed: objective, use of BIA, responsibility in their conduct, target audience, methodology and ethical code of practice while conducting and in the publication of results. An analysis of the differences between different national guidelines and their Polish counterparts was subsequently undertaken. RESULTS: Current international guidance for BIA is limited, often unclear and variable in terms of defining what constitutes BIA and how it should be undertaken. Australian PBAC guidelines for economic evaluation provide most detail into how BIA should be undertaken and reported. In comparison to existing guidance project of Polish BIA guidelines appears to be more detailed and includes recommendations on perspective, time horizon, reliability of data sources, reporting of results, rates of adoption of new therapies, probability of re-deploying resources. The intention was to establish principles for best practice in designing and implementing BIA. CONCLUSIONS: Whilst there is an increased demand for BIA, there is only limited guidance on how such studies should be undertaken. It is hoped, that the Polish guidelines can contribute to the development of such analyses and deliver benefit for Polish healthcare decision makers and beyond.
